Xiaochun Zhang

Dr. Xiaochun Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
QJQi Jin
Qi Jin
DCDandan Chen
Dandan Chen
XZXiaochun Zhang
Xiaochun Zhang
FZFeng Zhang
Feng Zhang
DZDongxiang Zhong
Dongxiang Zhong
JGJunbo Ge
Junbo Ge
Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

26 March 2025 in JACC: Asia
Verified
Journal Article
Open access
DLDawei Lin
Dawei Lin
QJQinchun Jin
Qinchun Jin
JMJiaxin Miao
Jiaxin Miao
ZLZhenzhen Li
Zhenzhen Li
JFJianing Fan
Jianing Fan
JGJunbo Ge
Junbo Ge
There is limited evidence regarding evidence of transcatheter tricuspid annuloplasty using K-Clip (Huihe Medical Technology) in tricuspid regurgitation (TR) patients with right ventricular-pulmonary arterial (RV-PA) uncoupling. This study sought to explore the role of transcatheter tricuspid annuloplasty in patients with RV-PA uncoupling. This was a retrospective observational study, including patients who underwent transcatheter annular repair successfully using the K-Clip device with RV-PA uncoupling at 9 centers in China. RV-PA uncoupling was characterized by a tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (PASP) ratio <0.55. Baseline information, imaging results, and their subsequent follow-up data were collected. All 81 patients (29 men, 72.6 ± 6.9 years of age) underwent successful intervention were enrolled in this study. During 30 days and 6 months follow-up, patients showed significant improvement in tricuspid annular plane systolic excursion/PASP rate (baseline vs 30 days: 0.40 ± 0.07 vs 0.50 ± 0.18; P < 0.001; baseline vs 6 months: 0.40 ± 0.07 vs 0.44 ± 0.11; P = 0.007) and decline in PASP comparing to those at baseline; patients with RV-PA uncoupling showed sustained improvement in TR status with significant improvement in life quality (NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores); 3 noncardiovascular deaths were documented, and the rate of adverse events during follow-up was acceptable. Transcatheter tricuspid annuloplasty showed a significant and durable improvement in TR in patients with RV-PA uncoupling. Significant improvement and decline are observed in RV-PA ratio and PASP, respectively. All-cause mortality and adverse event rates were acceptable, with sustained improvements in quality of life.

10 June 2025 in IJC Heart & Vasculature
Verified
Journal Article
Open access
ZLZhenzhen Li
Zhenzhen Li
DLDawei Lin
Dawei Lin
JMJiaxin Miao
Jiaxin Miao
JFJianing Fan
Jianing Fan
FLFanglin Lu
Fanglin Lu
JGJunbo Ge
Junbo Ge
This study evaluated the impact of transcatheter tricuspid valve replacement (TTVR) on renal and hepatic function in patients with severe tricuspid regurgitation (TR). TR is associated with increased morbidity, mortality, and heart failure-related hospitalizations. Venous congestion and reduced forward stroke volume can compromise hepatic and renal function. TTVR has emerged as a promising option for high-risk patients, but its effects remain understudied. In this prospective, multicenter study, 96 high-surgical-risk patients with severe TR (NYHA functional class III/IV) underwent LuX-Valve TTVR between September 2022 and March 2023. Follow-up at 7, 30, 180, and 360 days assessed cardiac, hepatic (total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)), and renal (serum creatinine, urea, uric acid) function. Procedural success was 95.79 %, and 93 patients survived to 12 months. All survivors exhibited TR reduction to less than grade III. Significant hepatic improvement was noted at 12 months, especially among those with preoperative liver dysfunction (LD): total bilirubin decreased from 21.54 ± 11.14 to 18.33 ± 7.82 μmol/L (P = 0.044) and direct bilirubin from 7.95 ± 4.74 to 5.92 ± 2.98 μmol/L (P = 0.005). Renal function remained stable. TTVR is an effective, minimally invasive approach for severe TR, facilitating significant hepatic recovery in patients with preoperative dysfunction while preserving renal function. These findings underscore the reversibility of TR-induced hepatic impairment and demonstrate TTVR’s potential to improve clinical outcomes.

6 January 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
QJQinchun Jin
Qinchun Jin
WLWei Li
Wei Li
SCShasha Chen
Shasha Chen
MLMingfei Li
Mingfei Li
DZDaxin Zhou
Daxin Zhou
JGJunbo Ge
Junbo Ge
Aims: The study aimed to compare paravalvular leak (PVL) changes after a transcatheter aortic valve replacement (TAVR) with self-expandable prosthesis between different aortic valve morphologies and evaluate the impact of paravalvular leak regression on clinical prognosis.Methods: Patients with aortic stenosis (AS) successfully treated with a self-expandable TAVR who were followed up for at least 1 year at our centre were consecutively enrolled from January 2016 to August 2019. Paired serial changes in paravalvular leak and other haemodynamic parameters by echocardiography were collected and compared between the bicuspid valve (BAV) and tricuspid aortic valve (TAV). A logistic regression model was used to explore the predictors of paravalvular leak regression (<1 grade) 1 year after transcatheter aortic valve replacement, while its impact on subsequent clinical outcomes (all-cause mortality and rehospitalisation for heart failure (HF)) was further evaluated using Kaplan–Meier analysis.Results: A total of 153 bicuspid valve and 114 tricuspid aortic valve patients were finally enrolled; haemodynamic parameters and paravalvular leak severity were comparable before the discharge between the two groups. The peak transaortic velocity, mean transvalvular gradient, and effective orifice area all significantly improved (p < 0.05) without intergroup differences at all follow-up timepoints. Significant paravalvular leak reduction was observed only in the TAV group (1.75% vs. 4.39%, p = 0.029), while moderate paravalular leak was still more prevalent in BAV (7.19% vs. 1.75%, p = 0.041) at the 1-year follow-up. Multivariable analyses identified the bicuspid valve, asymmetric calcification, and undersizing as independent predictors of failure of the 1-year paravalvular leak reduction in patients with mild or moderate paravalvular leak after discharge. Patients without a paravalvular leak reduction within 1 year showed a relatively higher 2-year all-cause mortality and HF (HR: 5.994, 95% CI: 1.691–21.240, and p = 0.053) rates thereafter.Conclusion: In AS patients after self-expandable transcatheter aortic valve replacement, paravalvular leak regression within 1 year was less prevalent in bicuspid valve morphology. The failure of paravalvular leak reduction might lead to an increased risk of poorer prognosis in the long run.

1 January 2024 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
YYYao Yao
Yao Yao
YLYanli Li
Yanli Li
QJQinchun Jin
Qinchun Jin
XLXiaoye Li
Xiaoye Li
XZXiaochun Zhang
Xiaochun Zhang
QLQianzhou Lv
Qianzhou Lv
Insufficient data exist regarding the investigation of the impact of novel oral anticoagulants (NOACs) on coagulation activation biomarkers in the context of left atrial appendage closure (LAAC) and device‐related thrombosis (DRT). The study was designed to investigate the changes and presence of coagulation activation biomarkers between different antithrombotic strategies following LAAC. A total of 120 nonvalvular atrial fibrillation patients intolerant of long‐term anticoagulants, who underwent successful WATCHMAN closure implantation, were enrolled (rivaroxaban, n = 82; dabigatran, n = 38). Blood samples were obtained from left atrium (LA) and left atrial appendage (LAA) during the operation and fasting blood samples on the same day of LAAC and 45 days after discharge. The biochemical indicators, thrombin‐antithrombin complex (TAT), soluble P‐selectin (sP‐selectin), von Willebrand factor (vWF), and CD40 ligand (CD40L), were measured by enzyme‐linked immunosorbent assay. The primary endpoints of this study were the efficacy and safety characteristics of different antithrombotic strategies, including DRT incidence, stroke or transient ischemic attack, systemic embolism, and clinical major and nonmajor bleeding complications during the follow‐up of 180 days. The results revealed that TAT, vWF, sP‐selectin, and CD40L levels in vein were significantly reduced by 2.4% (p = 0.043), 5.0% (p < 0.001), 8.7% (p < 0.001), and 2.5% (p = 0.043) from their baseline levels after rivaroxaban treatment. Conversely, no significant changes were detected in the dabigatran group. Furthermore, the plasma levels of platelet activation biomarkers (CD40L and sP‐selectin) in both LA and LAA groups were significantly lower after anticoagulation with rivaroxaban, as compared to dabigatran treatment (CD40L: 554.62 ± 155.54 vs. 445.02 ± 130.04 for LA p = 0.0013, 578.51 ± 156.28 vs. 480.13 ± 164.37 for LAA p = 0.0052; sP‐selectin: 2849.07 ± 846.69 vs. 2225.54 ± 799.96 for LA p = 0.0105, 2915.52 ± 1402.40 vs. 2203.41 ± 1061.67 for LAA p = 0.0022). Notably, the present study suggests that rivaroxaban may be more effective in the prevention of DRT for patients undergoing LAAC.

2 January 2025 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
YYYao Yao
Yao Yao
QJQinchun Jin
Qinchun Jin
XZXiaochun Zhang
Xiaochun Zhang
QLQianzhou Lv
Qianzhou Lv
The main objective of this study was to investigate the optimal post-left atrial appendage closure (LAAC) anticoagulation strategy, focusing on minimizing device-related thrombosis (DRT) and thromboembolism (TE) events without increasing bleeding risk. After successful LAAC, consecutive participants were treated with 45-day anticoagulants (rivaroxaban 15 mg daily, dabigatran 110 mg twice a day, and warfarin). The efficacy endpoints included DRT, TE, and hospital readmissions due to cardiac caused, while safety endpoints encompassed bleeding events, monitored over a 12-month follow-up period. The incidence of DRT was relatively lower in the rivaroxaban group compared to both the dabigatran and warfarin groups (rivaroxaban vs. dabigatran: HR = 0.504, 95% CI 0.208–1.223, log-rank P = 0.101; rivaroxaban vs. warfarin: HR = 0.468, 95% CI 0.167–1.316, log-rank P = 0.093). The median [interquartile range] length and width of DRT in the rivaroxaban group were 1.92 [1.68–2.15] mm and 1.49 [1.28–1.76] mm, both significantly lower than those in the dabigatran (length = 2.15 [1.99–2.25] mm, P = 0.036; width = 1.60 [1.54–1.85] mm, P = 0.035) and warfarin groups (length = 2.26 [2.11–2.44] mm, P = 0.006; width = 1.74 [1.54–1.85] mm, P = 0.006). Kaplan-Meier survival analysis indicated that procedural bleeding was more common in the warfarin group. The 12-month incidence of TE was significantly lower in the rivaroxaban group compared to the dabigatran (HR = 0.466, 95% CI 0.221–0.984, log-rank P = 0.029) and warfarin groups (HR = 0.456, 95% CI 0.188–0.966, log-rank P = 0.042). Long-term antithrombotic therapy with reduced dose of rivaroxaban significantly reduced the risk of DRT and composite endpoints without increasing bleeding events, compared to warfarin and dabigatran, for patients following LAAC.